Comparing the current results to its competitors, Biontech Se reported Revenue increase in the 4 quarter 2025 by 4.32 % year on year. The revenue growth was below Biontech Se's competitors' average revenue growth of 7.22 %, achieved in the same quarter.
Biontech Se's Comment on Competition and Industry Peers
The company operates in a highly competitive industry characterized by rapidly advancing technologies and a complex intellectual property environment. Its competitors include large and specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies, and both public and private research organizations. Many of these competitors possess greater capabilities in scientific research, product development, financial resources, marketing, sales, and human resources. Additionally, smaller or early-stage companies, particularly those focused on immunotherapy therapeutics, may pose significant competition, often through collaborations with larger firms. Notably, some collaborators such as Genmab and Pfizer also compete with the company in certain markets. Competitors may achieve greater success in developing and commercializing technologies, gaining market acceptance, creating more effective or safer products, or obtaining regulatory approvals more rapidly, which could limit the company's commercial opportunities.
Overall company revenue, grew less, than total company revenues, at 4.32 % and company approximately market share, declined to 3.46 %. << More on BNTX Market Share.
*Market share is calculated based on total revenue.
November 13, 2024
In a proactive move to enhance its oncology strategy, BioNTech SE has announced its decision to acquire Biotheus, a company known for its innovative therapeutic approaches in cancer treatment. This acquisition comes at a time when BioNTech is navigating challenges regarding its return on investment (ROI), with recent reports indicating a significant decline in financial performance. BioNTech s Q4 Financial Overview In the fourth quarter of 2023, BioNTech recorded an ROI of 4.44%, marking a notable drop compared to its historical average ROI of 15.38%. This decrease indicates that while the company experienced growth in net income from the previous quarter, the overall efficiency of its invested assets did no...
September 4, 2024
Tempus Announces Real-World Data Collaboration with BioNTech CHICAGO - Tempus AI, Inc. (NASDAQ: TEM, Tempus), a forefront technology company spearheading the adoption of artificial intelligence (AI) to enhance precision medicine and patient care, has declared a strategic multi-year collaboration with BioNTech SE (Nasdaq: BNTX, BioNTech), a global leader in next-generation immunotherapy pioneering innovative treatments for cancer and other severe diseases. This partnership aims to leverage Tempus comprehensive multimodal datasets to support BioNTech s future-oriented oncology pipeline.The collaboration marks a significant milestone in the convergence of AI and oncology, promising to accelerate the developmen...
August 22, 2024
In a significant development in the ongoing fight against COVID-19, Pfizer Inc. and BioNTech SE have achieved a major milestone with the approval of their Omicron KP.2-adapted COVID-19 vaccine by the U.S. Food and Drug Administration (FDA). Announced from their respective headquarters in New York and Mainz, Germany, this decision marks a pivotal advancement in public health, especially as concerns about evolving variants continue to grow.The FDA has granted approval for the supplemental Biologics License Application (BLA) for the vaccine, branded as COMIRNATY (COVID-19 Vaccine, mRNA), for individuals aged 12 years and older. Additionally, it has provided emergency use authorization for the Pfizer-BioNTech CO...
August 16, 2024
In the recent interim report for H1 2024, BioNTech SE has revealed a notable decline in its return on average invested assets (ROI), registering at 4.44% for the fourth quarter of 2023. This figure is markedly below the company’s typical ROI, which averages around 15.38%. This drop raises pertinent questions regarding the company’s financial performance and overall competitiveness in the rapidly evolving healthcare sector.Despite achieving net income growth in the fourth quarter, BioNTech SE experienced a decrease in ROI compared to the previous quarter, signaling potential difficulties in capital efficiency or investment success. The financial landscape for BioNTech appears even more challenging when co...
July 22, 2024
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024MAINZ, Germany, July 22, 2024 - BioNTech SE (Nasdaq: BNTX, BioNTech or the Company) has announced that it will be releasing its financial results for the second quarter of 2024 on Monday, August 5, 2024. Alongside the financial report, the Company will be hosting a conference call and webcast at 8:00 a.m. EDT (2:00 p.m. CEST) on the same day. This event is open to investors, financial analysts, and the general public. The purpose of the call and webcast will be to discuss the financial results and provide a corporate update.This announcement comes on the heels of BioNTech s recent collaboration with Genmab A/S in t...
June 24, 2024
MAINZ, Germany and SHANGHAI, China June 24, 2024 BioNTech SE (Nasdaq: BNTX, BioNTech) and Duality Biologics (Suzhou) Co., Ltd. (DualityBio) have announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for their antibody-drug conjugate candidate, BNT324/DB-1311. This innovative candidate targets advanced/unresectable or metastatic castration-resistant prostate cancer (CRPC) in patients who have shown progression following standard systemic treatments.BNT324/DB-1311 is a next-generation antibody-drug conjugate (ADC) that targets the transmembrane glycoprotein B7-H3. B7-H3 is an immune checkpoint protein overexpressed in various tumor types and is linked with disease ...
June 1, 2024
Investigational Acasunlimab (DuoBody -PD-L1x4-1BB) in Combination with Pembrolizumab Shows Promising Results in Phase 2 Trial for Previously Treated Metastatic Non-small Cell Lung CancerCOPENHAGEN, Denmark, and MAINZ, Germany, June 1, 2024 - Genmab A/S (Nasdaq: GMAB) and BioNTech SE (Nasdaq: BNTX) have recently announced the preliminary results of their ongoing Phase 2 trial (NCT05117242) evaluating the combination of acasunlimab (DuoBody-PD-L1x4-1BB), a novel bispecific antibody also known as GEN1046/BNT311, and pembrolizumab for the treatment of metastatic non-small cell lung cancer (mNSCLC) patients who have previously failed anti-PD(L)1 therapies.The data presented at the 2024 American Society of Clinica...
Immunome Inc is a biotechnology company that focuses on developing novel immunotherapies. Their business model revolves around leveraging their proprietary discovery engine to identify therapeutic antibodies for infectious diseases and cancer. By collaborating with partners and through their own clinical development efforts, they aim to bring these promising treatments to the market.
Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of novel vaccines. They aim to leverage their proprietary recombinant nanoparticle vaccine technology platform to address a wide range of infectious diseases. By collaborating with partners and conducting clinical trials, Novavax works towards bringing innovative vaccines to the global market.
Omega Therapeutics Inc is a biotechnology company that focuses on developing therapies by leveraging the power of epigenetics. Their business model involves utilizing their proprietary Omega Epigenomic Programming technology to target specific genes and modulate their activity, addressing complex diseases at their source. By creating innovative and precise therapeutic interventions, Omega Therapeutics aims to make significant advancements in healthcare.
Vaxcyte Inc's business model revolves around developing and commercializing vaccines to prevent diseases with a focus on advancing innovative approaches to address unmet medical needs. They aim to create value by leveraging their scientific expertise, conducting clinical studies, obtaining regulatory approvals, and efficiently manufacturing and distributing vaccines worldwide.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Sources:
Biontech Se’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Biontech Se versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
